This event is being co-organized with the American Association for the Study of Liver Diseases (AASLD)
Hepatologists, virologists, translational and clinical researchers, health professionals, young trainees.
Epidemiology, Pathogenesis and Virology, HCV Assessment and Treatment, Special Patient Populations, Clinical and Translational Research
It is our pleasure to welcome you to the European Association for the Study of the Liver (EASL)-American Association for the Study of Liver Diseases (AASLD) Special Conference entitled “NEW PERSPECTIVES IN HEPATITIS C VIRUS INFECTION - THE ROADMAP FOR CURE” which will take place in Paris, France on September 23-24, 2016.
The recent and rapid advances in the treatment of hepatitis C have completely changed the scenario of this disease in the last months. It is not always easy to be updated in the field, due to the huge amount of data coming from a large number of published studies. Antiviral drugs that are still not approved in some countries are already classified as “old” and current treatment regimens may be replaced by new ones by the time the meeting takes place. The aim of this conference is to summarize the information available, as well as to provide a critical review and analysis of the best available (some unpublished data will be relevant) data. With this goal in mind, this meeting will give hepatologists, as well as other specialists interested in hepatitis C, the opportunity to catch up with the new advances in the field and be able to apply them in clinical practice. To reach this aim, an international panel of key experts and participants will actively interact to resolve pending issues and to highlight areas needing further analysis and investigation.
Central issues that will be addressed include:
The Scientific Committee
Prof. Dr Thomas Berg, Leipzig, Germany
Dr Raymond T. Chung, Boston, MA, USA
Dr Xavier Forns, Barcelona, Spain
Dr Norah Terrault, San Francisco, CA, USA
Management of Hepatitis C Virus Infection
Next EASL events
The number of people living with viral hepatitis in increasing
Direct acting antivirals: do they work beyond sustained virological response in chronic hepatitis C patients?